-+ 0.00%
-+ 0.00%
-+ 0.00%

Enliven Therapeutics Q4 EPS $(0.48) Misses $(0.38) Estimate

Benzinga·03/03/2026 21:14:54
Listen to the news
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 27.32 percent. This is a 4.35 percent decrease over losses of $(0.46) per share from the same period last year.